The scientific community should lobby to be able to apply for drug licences

BMJ (Online)

Volumn 344, Issue 7858, 2012, Pages

  Garattini, Silvio ^a   Bertele, Vittorio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

COMMERCIAL PHENOMENA; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; EUROPEAN UNION; EXPECTATION; HEALTH CARE NEED; LETTER; LICENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; DRUG APPROVAL; HUMAN; LICENSING; POLITICS; UNITED KINGDOM;

DRUG APPROVAL; EUROPEAN UNION; GREAT BRITAIN; HUMANS; LICENSURE, PHARMACY; LOBBYING;

EID: 84861494429     PISSN: 17561833     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.e3553     Document Type: Letter

References (5)

1. Torjesen I. Why using Avastin for eye disease is so difficult. BMJ 2012;344:e3012. (1 May.)
2. Torjesen I. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD. BMJ 2012;344:e2959. (24 April.)
3. Campbell RJ, Dhalla IA, Gill SS, Bell CM. Implications of "not me" drugs for health systems: lessons from age related macular degeneration. BMJ 2012;344:e2941. (1 May.)
4. Godlee F. Avastin versus Lucentis [Editor's choice]. BMJ 2012;344:e3162. (2 May.)
5. Garattini S, Bertele' V. A matter of public interest. BMJ 2010;341:c3721.